Ziopharm Oncology In (ZIOP) 5.93 $ZIOP
ZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Mon Jun 27, 3:05PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the successful completion of enrollment in the first and second dosing cohorts as well as the initiation of enrollment in a third cohort in the Company's ongoing multi-center Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex to treat recurrent or progressive glioblastoma (GBM) or grade III malignant glioma. Ad-RTS-hIL-12 + veledimex is a novel viral gene therapy candidate for the controlled expression of interleukin 12 (IL-12), a critical protein for stimulating an anti-cancer immune response.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 2:00 p.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Wed May 18, 4:04PM CDT
- Data to be Presented at the 2016 ASCO Annual Meeting -
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Ziopharm reports 1Q loss
Automated Insights - Tue May 10, 4:28PM CDT
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Tuesday reported a loss of $12 million in its first quarter.
ZIOP: 5.93 (-0.11)
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue May 10, 4:08PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company's recent activities.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 5.93 (-0.11), CLDX: 4.57 (-0.07), XON: 26.23 (-0.49), MNKD: 1.14 (-0.03)
ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting
GlobeNewswire - Mon Apr 18, 11:40AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will be presented in oral sessions at the upcoming 19 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The first presentation highlights preclinical data from the Company's novel viral gene therapy candidate for the controlled expression of IL-12 in combination with inhibition of programmed cell death protein 1 (PD-1) in a mouse model of glioma. The second presentation highlights preclinical data from the Company's evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia. The ASGCT meeting will take place May 4-7 at the Marriott Wardman Park Hotel in Washington, D.C.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit
GlobeNewswire - Thu Mar 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2 Annual Immuno-Oncology Summit on Thursday, April 7, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.
ZIOP: 5.93 (-0.11)
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 18, 8:03AM CDT
Image source: Flickr user Hobvias Sudoneighm. The easiest investment strategy, and the one that's proven to work best over the long run, is to pick out high-quality businesses and hold them for long periods of time. However, for some investors the...
ZIOP: 5.93 (-0.11), INSY: 15.18 (-0.48), SRPT: 21.37 (-1.25), RLYP: 20.25 (+0.08), MNKD: 1.14 (-0.03)
Could Cancer Deaths Really Be Eliminated for People Under the Age of 80 by 2050?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 13, 8:12AM CDT
Image source: Pixabay. Cancer. It's potentially the scariest diagnosis a person can receive from their doctor, but it's something roughly 14 million people around the world will hear this year, according to the World Health Organization. In a...
ZIOP: 5.93 (-0.11), MYGN: 32.06 (+0.37), MRK: 59.34 (-0.01), XON: 26.23 (-0.49), EXAS: 12.60 (+0.17), BMY: 75.39 (+0.11)
Why Ziopharm Oncology Soared 49% In February
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 08, 3:02PM CST
SOURCE: MD ANDERSON CANCER CENTER W hat: After reporting that the first patient has been dosed with its second generation CAR-T cancer killing therapy on Feb. 9 and releasing its fourth quarter financials on Feb. 24, Ziopharm Oncology ...
ZIOP: 5.93 (-0.11), KITE: 47.68 (-0.85), XON: 26.23 (-0.49), JUNO: 27.28 (-0.53)
Last Week's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:00PM CST
IMAGE BY TBIT VIA PIXABAY. It was another good week to be a healthcare-focused investor. as many of the most popular exchange-traded funds that concentrate on the sector continued to recover from their dreadful start to the year. Several of these...
MDVN: 62.23 (+0.13), ZIOP: 5.93 (-0.11), XBI: 57.35 (-0.24)
BUYINS.NET: ZIOP, CROX, CVLT, ANW, HTS, NYMT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 09, 7:10AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Crocs Inc (NASDAQ:CROX), CommVault Systems Inc (NASDAQ:CVLT), Aegean Marine Petroleum Network Inc (NYSE:ANW), Hatteras Financial Corp (NYSE:HTS), New York Mortgage Trust Inc (NASDAQ:NYMT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ANW: 6.14 (+0.24), CROX: 12.02 (+0.29), ZIOP: 5.93 (-0.11), HTS: 16.31 (+0.11), CVLT: 44.53 (+0.30), NYMT: 6.16 (+0.09)
ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies
GlobeNewswire - Tue Feb 09, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Waging War on the Greatest Cancer Myth of All
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 07, 8:12AM CST
Image source: National Cancer Institute. In terms of medical diagnoses, there aren't many things scarier than hearing the phrase, "you have cancer." The numbers partially tell the tale. Globally, according to the World Health Organization, there...
ZIOP: 5.93 (-0.11), MRK: 59.34 (-0.01), XON: 26.23 (-0.49), BMY: 75.39 (+0.11)
ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 1:00 p.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics, and Vertex Pharma
ACCESSWIRE - Mon Feb 01, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Park Lane Advisor has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), PTC Therapeutics Inc. (NASDAQ: PTCT), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research report on ZIOPHARM Oncology can be accessed at http://www.parklaneadvisor.com/ On Friday, January 29, 2016, the NASDAQ Composite ended at 4,613.95, up 2.38%, the Dow Jones Industrial Average advanced 2.47%, to finish the day at 16,466.30, and the S&P 500 closed at 1,940.24, up 2.48%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
VRTX: 90.10 (+1.14), ZIOP: 5.93 (-0.11), BMRN: 88.59 (-2.90), PTCT: 7.47 (-0.06)
3 Healthcare Technologies That Are Set to Transform Our Lives Over the Next 10 Years
Selena Maranjian, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Sun Jan 31, 10:03AM CST
Photo: Derek Bridges , Flickr Technology seems to change everything, doesn't it? In transportation, for example, innovations such as electric trolleys, automobiles, steam engines, railroads, and airplanes made our travels faster, safer, and more...
EYES: 4.15 (+0.09), ZIOP: 5.93 (-0.11), ZBH: 125.04 (+0.15), XON: 26.23 (-0.49), SYK: 122.61 (+0.32)
ZIOPHARM Announces Sleeping Beauty Non-Viral Gene Transfer Technology Featured in Nature Medicine
GlobeNewswire - Mon Jan 11, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that its Sleeping Beauty non-viral gene transfer technology was featured in a perspectives article in the January 2016 issue of the journal Nature Medicine (Volume 22, Number 1, 26-36), titled "Prospects for gene-engineered T cell immunotherapy for solid cancers".
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM to Present at the 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 06, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence J.N. Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th, 2016 at 1:30 p.m. PT at The Westin St. Francis in San Francisco, CA.
ZIOP: 5.93 (-0.11), JPM: 62.27 (+0.44), XON: 26.23 (-0.49)
ZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Mon Jun 27, 3:05PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the successful completion of enrollment in the first and second dosing cohorts as well as the initiation of enrollment in a third cohort in the Company's ongoing multi-center Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex to treat recurrent or progressive glioblastoma (GBM) or grade III malignant glioma. Ad-RTS-hIL-12 + veledimex is a novel viral gene therapy candidate for the controlled expression of interleukin 12 (IL-12), a critical protein for stimulating an anti-cancer immune response.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 2:00 p.m. ET. The conference is being held at the Grand Hyatt Hotel in New York City.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
GlobeNewswire - Wed May 18, 4:04PM CDT
- Data to be Presented at the 2016 ASCO Annual Meeting -
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Ziopharm reports 1Q loss
Automated Insights - Tue May 10, 4:28PM CDT
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Tuesday reported a loss of $12 million in its first quarter.
ZIOP: 5.93 (-0.11)
ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities
GlobeNewswire - Tue May 10, 4:08PM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company's recent activities.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Ignore MannKind Corp.: Here Are 3 Better Stocks
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 25, 9:01AM CDT
Image source: MannKind Corp. I've never seen an independent auditor report so grim as MannKind 's latest. The maker of inhalable insulin Afrezza has been in dire shape ever since marketing partner Sanofi ended their collaboration agreement,...
ZIOP: 5.93 (-0.11), CLDX: 4.57 (-0.07), XON: 26.23 (-0.49), MNKD: 1.14 (-0.03)
ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting
GlobeNewswire - Mon Apr 18, 11:40AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will be presented in oral sessions at the upcoming 19 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The first presentation highlights preclinical data from the Company's novel viral gene therapy candidate for the controlled expression of IL-12 in combination with inhibition of programmed cell death protein 1 (PD-1) in a mouse model of glioma. The second presentation highlights preclinical data from the Company's evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia. The ASGCT meeting will take place May 4-7 at the Marriott Wardman Park Hotel in Washington, D.C.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit
GlobeNewswire - Thu Mar 31, 6:00AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2 Annual Immuno-Oncology Summit on Thursday, April 7, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.
ZIOP: 5.93 (-0.11)
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 18, 8:03AM CDT
Image source: Flickr user Hobvias Sudoneighm. The easiest investment strategy, and the one that's proven to work best over the long run, is to pick out high-quality businesses and hold them for long periods of time. However, for some investors the...
ZIOP: 5.93 (-0.11), INSY: 15.18 (-0.48), SRPT: 21.37 (-1.25), RLYP: 20.25 (+0.08), MNKD: 1.14 (-0.03)
Could Cancer Deaths Really Be Eliminated for People Under the Age of 80 by 2050?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 13, 8:12AM CDT
Image source: Pixabay. Cancer. It's potentially the scariest diagnosis a person can receive from their doctor, but it's something roughly 14 million people around the world will hear this year, according to the World Health Organization. In a...
ZIOP: 5.93 (-0.11), MYGN: 32.06 (+0.37), MRK: 59.34 (-0.01), XON: 26.23 (-0.49), EXAS: 12.60 (+0.17), BMY: 75.39 (+0.11)
Why Ziopharm Oncology Soared 49% In February
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 08, 3:02PM CST
SOURCE: MD ANDERSON CANCER CENTER W hat: After reporting that the first patient has been dosed with its second generation CAR-T cancer killing therapy on Feb. 9 and releasing its fourth quarter financials on Feb. 24, Ziopharm Oncology ...
ZIOP: 5.93 (-0.11), KITE: 47.68 (-0.85), XON: 26.23 (-0.49), JUNO: 27.28 (-0.53)
Last Week's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:00PM CST
IMAGE BY TBIT VIA PIXABAY. It was another good week to be a healthcare-focused investor. as many of the most popular exchange-traded funds that concentrate on the sector continued to recover from their dreadful start to the year. Several of these...
MDVN: 62.23 (+0.13), ZIOP: 5.93 (-0.11), XBI: 57.35 (-0.24)
BUYINS.NET: ZIOP, CROX, CVLT, ANW, HTS, NYMT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 09, 7:10AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Crocs Inc (NASDAQ:CROX), CommVault Systems Inc (NASDAQ:CVLT), Aegean Marine Petroleum Network Inc (NYSE:ANW), Hatteras Financial Corp (NYSE:HTS), New York Mortgage Trust Inc (NASDAQ:NYMT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ANW: 6.14 (+0.24), CROX: 12.02 (+0.29), ZIOP: 5.93 (-0.11), HTS: 16.31 (+0.11), CVLT: 44.53 (+0.30), NYMT: 6.16 (+0.09)
ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies
GlobeNewswire - Tue Feb 09, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Waging War on the Greatest Cancer Myth of All
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 07, 8:12AM CST
Image source: National Cancer Institute. In terms of medical diagnoses, there aren't many things scarier than hearing the phrase, "you have cancer." The numbers partially tell the tale. Globally, according to the World Health Organization, there...
ZIOP: 5.93 (-0.11), MRK: 59.34 (-0.01), XON: 26.23 (-0.49), BMY: 75.39 (+0.11)
ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 1:00 p.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics, and Vertex Pharma
ACCESSWIRE - Mon Feb 01, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Park Lane Advisor has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), PTC Therapeutics Inc. (NASDAQ: PTCT), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research report on ZIOPHARM Oncology can be accessed at http://www.parklaneadvisor.com/ On Friday, January 29, 2016, the NASDAQ Composite ended at 4,613.95, up 2.38%, the Dow Jones Industrial Average advanced 2.47%, to finish the day at 16,466.30, and the S&P 500 closed at 1,940.24, up 2.48%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
VRTX: 90.10 (+1.14), ZIOP: 5.93 (-0.11), BMRN: 88.59 (-2.90), PTCT: 7.47 (-0.06)
3 Healthcare Technologies That Are Set to Transform Our Lives Over the Next 10 Years
Selena Maranjian, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Sun Jan 31, 10:03AM CST
Photo: Derek Bridges , Flickr Technology seems to change everything, doesn't it? In transportation, for example, innovations such as electric trolleys, automobiles, steam engines, railroads, and airplanes made our travels faster, safer, and more...
EYES: 4.15 (+0.09), ZIOP: 5.93 (-0.11), ZBH: 125.04 (+0.15), XON: 26.23 (-0.49), SYK: 122.61 (+0.32)
ZIOPHARM Announces Sleeping Beauty Non-Viral Gene Transfer Technology Featured in Nature Medicine
GlobeNewswire - Mon Jan 11, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that its Sleeping Beauty non-viral gene transfer technology was featured in a perspectives article in the January 2016 issue of the journal Nature Medicine (Volume 22, Number 1, 26-36), titled "Prospects for gene-engineered T cell immunotherapy for solid cancers".
ZIOP: 5.93 (-0.11), XON: 26.23 (-0.49)
ZIOPHARM to Present at the 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 06, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence J.N. Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th, 2016 at 1:30 p.m. PT at The Westin St. Francis in San Francisco, CA.
ZIOP: 5.93 (-0.11), JPM: 62.27 (+0.44), XON: 26.23 (-0.49)
